Hepatoid adenocarcinoma of the lung (HAL) is an extremely rare cancer without clear treatment guidance and with a poor prognosis. This report discusses a 64-year-old man who presented with complaints of hemoptysis and was found to have a right upper lobe (RUL) lung mass on chest CT with presence of a right hilar mass and retrocaval lymphadenopathy, and metastasis to the vertebral spine and rib. The patient was diagnosed with T2N2M1 (stage IV) unresectable disease. A biopsy of the RUL mass revealed hepatoid variant adenocarcinoma. Immunohistochemical stains showed tumor cells positive for CK7, AFP, Hep Par 1, napsin A, and cytoplasmic TTF-1 staining. In contrast, CK5, CK6, and CK20 were negative, and EGFR was wild-type. Serum alpha fetoprotein (AFP) level was elevated at 181 ng/mL. The patient was treated with platinum-based doublet chemotherapy and sorafenib, and his AFP level decreased to 25 ng/mL. This case report presents the novel use of sorafenib in combination with platinum-based doublet chemotherapy in EGFR wild-type HAL, which led to a partial response. Single-agent sorafenib led to stable disease overall, achieving a survival among the longest reported for unresectable stage IV, all while maintaining an ECOG performance status of 0 to 1.
Tatjana Gavrancic and Yeun-Hee Anna Park
the second paragraph of the Newly Diagnosed Advanced Disease section should have read “Single-agent cisplatin plus radiotherapy is effective and easy to administer, and typically uses conventional fractionation at 2.0 Gy /fraction to 70 Gy or more in
scientific peer-review process and are overseen by the ORP. An NCCN study funded through the grant mechanism is highlighted below. A Randomized Phase II Study of Single-Agent Dabrafenib (BRAFi) Versus Combination-Regimen Dabrafenib (BRAFi) and
scientific peer-review process and are overseen by the ORP. NCCN studies funded through the grant mechanism are highlighted below. A Randomized Phase 2 Study of Single-Agent GSK2118436 (BRAFi) vs. Combination Regimen GSK2118436 (BRAFi) and GSK1120212
: Nikhil I. Khushalani, MD Conditions: Recurrent melanoma; stage IIIA, IIIB, IIIC, and IV melanoma Institution: Roswell Park Cancer Institute This is a phase II study of single-agent axitinib in the treatment of patients with advanced melanoma to
762 762 0050753 10.6004/jnccn.2007.0067 Point: Combination Versus Single-Agent Chemotherapy: The Argument for Sequential Single Agents Conlin Alison K. MD, MPH Seidman Andrew D. MD 09 2007 5 5 8 8 766 766 770 770 0050766 10.6004/jnccn
Michael B. Streiff, Bjorn Holmstrom, Dana Angelini, Aneel Ashrani, Paula L. Bockenstedt, Carolyn Chesney, John Fanikos, Randolph B. Fenninger, Annemarie E. Fogerty, Shuwei Gao, Samuel Z. Goldhaber, Krishna Gundabolu, Paul Hendrie, Alfred I. Lee, Jason T. Lee, Janelle Mann, Brandon McMahon, Michael M. Millenson, Colleen Morton, Thomas L. Ortel, Sadat Ozair, Rita Paschal, Sanford Shattil, Tanya Siddiqi, Kristi J. Smock, Gerald Soff, Tzu-Fei Wang, Eliot Williams, Anaadriana Zakarija, Lydia Hammond, Mary A. Dwyer and Anita M. Engh
-associated VTE. Several prospective randomized studies have compared the efficacy and safety of single-agent LMWH (for initial and long-term treatment) versus combination therapy with initial LMWH or unfractionated heparin (UFH) plus long-term treatment with
: Determine overall response rate of single-agent weekly CFZ, measured after 2 cycles of therapy, in WM and MZL Secondary Objectives: Assess safety and tolerability of single-agent weekly CFZ in patients with WM and MZL, and determine the
III and stage IV melanoma Institution: Roswell Park Cancer Institute This is a phase II study to determine the efficacy and safety of single-agent axitinib in the treatment of patients with advanced melanoma. Primary Objective: Determine the
Robert J. Morgan Jr.
. Similarly, results from phase II nonrandomized trials are often sufficient to result in the addition of an active single agent to the recommendations for treating recurrence. Comparison of the available agents for recurrence therapy in 1995 with those in